Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

Summary

This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.

Detailed Description

PRIMARY OBJECTIVES: I. Generate induced pluripotent stem cells (iPSC's) from patients receiving cancer treatment. II. Differentiate patient iPSC's into cardiomyocytes and/or neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects, such as cardiotoxicity and neurotoxicity. III. Use patient specific iPSC-derived cells to: IIIa. Model cancer therapy-related toxicities; IIIb. Better understand the mechanisms of toxicities; IIIc. Determine if patient specific genetic variants are causative of toxicities; IIId. Screen novel protective therapies for cancer therapy-related toxicities. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.

Eligibility Criteria

Interventions